drugset / Trial / NCT07223424
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RandomizedCrossoverOpen-labelTreatment
Summary
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Timeline
- Start
- 2025-11-04
- Primary completion
- 2030-11-30
- Completion
- 2030-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Comparator | Nivolumab | Monoclonal antibody | 1200 mg | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | 790 mg | Intravenous |